Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a ...

Celltrion negotiates patent deal after German court halts Eydenzelt sales Celltrion says talks under way to settle patents ...

Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial. Now, the ...

The firm now models $4.35 billion in U.S. Eylea franchise revenues for 2026, well above the $3.86 billion consensus. BofA also highlighted upside from Dupixent, noting it “continues to deliver growth” ...

Regeneron Pharmaceuticals, Inc. REGN recently announced that its supplemental biologics license application (sBLA) for the ophthalmology drug, Eylea (aflibercept), has been accepted by the FDA for ...

Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eylea HD improved vision with extended dosing intervals ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...